Proportion of patients with implanted permanent pacemakers with atrial fibrillation receiving appropriate medical prophylaxis in North Wales

Pacing Clin Electrophysiol. 2012 Aug;35(8):935-42. doi: 10.1111/j.1540-8159.2012.03430.x. Epub 2012 May 31.

Abstract

Background: Atrial fibrillation (AF) is associated with an increased long-term risk of stroke, heart failure, and mortality. Previous studies have demonstrated the suboptimal use of anticoagulation therapy in patients with AF.

Methods: A retrospective survey of patients (N = 1,113) fitted with dual-chamber pacemakers found 71 patients (age 69 ± 35, mean ± standard deviation) with atrial tachycardia and AF (defined as >5 minutes per day). Their medical records and anticoagulation status were investigated and used to stratify each patient for stroke risk with the Birmingham 2009 schema (CHA(2)DS(2)-VASc) and assessed to determine the rate of appropriate thromboembolism (TE) prophylaxis prescription.

Results: The most common overall concomitant risk factor for stroke was hypertension (54%), followed by age ≥75 (51%), being female and previous stroke/transient ischemic attack/TE (39%). The average CHA(2)DS(2)-VASc score was 3.7 ± 1.6. Fifty-six percent of the patients were not receiving appropriate anticoagulation therapy.

Conclusion: This study demonstrates an underutilization of the oral anticoagulant warfarin in patients with known AF and that the clinicians may not be regarding current stroke risk factors when adopting a thromboprophylaxis strategy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / therapy*
  • Female
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Humans
  • Hypertension / complications
  • Incidence
  • Male
  • Middle Aged
  • Pacemaker, Artificial*
  • Retrospective Studies
  • Risk
  • Sex Factors
  • Stroke / etiology
  • Stroke / prevention & control
  • Tachycardia / therapy
  • Thromboembolism / prevention & control
  • Wales / epidemiology
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin